Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
allogeneic cell therapy
Biotech
Vor Bio's dual stem cell, ADC shows consistent engraftment
Vor Bio plans to accelerate enrollment of a phase 1/2 trial of its dual stem cell-ADC cancer therapy to get a fuller picture of post-relapse response.
Max Bayer
Nov 9, 2023 4:10pm
AbbVie ends Caribou CAR-T deal, continuing cascade of axed pacts
Sep 27, 2023 6:00am
Calidi goes public via SPAC to push allogeneic cancer therapies
Sep 13, 2023 9:35am
Precision punts early-phase CAR-T to Imugene for $21M upfront
Aug 16, 2023 4:00am
Precision on the partnership prowl for lead asset after FDA chat
Jul 27, 2023 10:57am
Pfizer pours $25M investment into Caribou CAR-Ts
Jul 6, 2023 8:00am
